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A Variant t(14;17) in Acute Promyelocytic 
Leukemia 
Positive Response to Retinoic Acid Treatment 
J. C. Cigudosa, M. J. Calasanz, M. D. Odero, J. Marin, 
E. Bengoechea, and A. Gull6n 
ABSTRACT: We present a case of acute promyelocytic leukemia (APL) carrying an atypical transloca- 
tion involving chromosomes 14 and 17. This translocation could be considered a variant of the APL- 
specific t(15; 17). Positive response to retinoic acid treatment suggests molecular rearrangement of retinoic 
acid receptor a. 
INTRODUCTION 
The most recurrent chromosomal rearrangement found in 
acute promyelocytic leukemia (APL) is t(15; 17) (q2 2 ;q21). 
Since this specificity was established [1], several reports have 
described simple variant and complex translocations in APL 
[2- 7]. Molecular studies of the t(15; 17) have shown that the 
retinoic acid receptor a (RARa) gene located on chromosome 
17 is rearranged and recombined in a novel gene, named 
PML, on chromosome 15. It generates the PML/RARa fusion 
gene, which is then transcribed into PML/RARa fusion 
mRNA (reviewed in [8]). There findings were made closely 
after the observations of the striking efficacy of all-trans- 
retinoic acid in the treatment of a patient with APL [8] and 
they illustrate advancements in cancer research that may 
cause immediate changes in the treatment of the disease. 
We here report a case of APL showing a variant ranslo- 
cation involving, at the cytogenetic level, chromosomes 14 
and 17. In the absence of molecular studies, the patient's re- 
sponse to retinoic acid treatment suggests the rearrangement 
of the RARa gene, in the same way as it occurs in a common 
APL with the t(15;17). 
MATERIALS AND METHODS 
Case Report 
A 26-year-old man was admitted in August 1993 with ecchy- 
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mosis affecting both arms. His complete blood count showed 
a white blood cell count of 5.4 x 10S/L with 41% blasts, a 
hemoglobin of 13.1 g/dL, and a platelet count of 14 x 109/L. 
He also presented a disseminated intravascular coagulation 
profile. The bone marrow aspirate was compatible with a di- 
agnosis of ANLL of the M3 FAB subtype. Immunologic mark- 
ers were CD13 96% and CD33 93%. 
After 1 month of conventional chemotherapy (farmi- 
blastine and cytarabine), hematologic remission was not 
achieved by 9/27/93 and treatment with retinoic acid (50 mg 
every 12 hours) was started. Two weeks later, the white blood 
cell count rose to 14.9 x 10S/L and treatment with retinoic 
acid and chemotherapy (cytarabine, M-AMSA, and thyogua- 
nine) was followed. After 38 days of retinoic acid treatment 
and 21 days of chemotherapy heentered complete remission. 
Finally, he received aconsolidation chemotherapy c cle with 
the same drugs mentioned above. The patient hen left the 
hospital and underwent a bone marrow transplantation 
program. 
Cytogenetic Results 
Bone marrow cells were short-term cultured (24-48 hours) 
and analyzed by standard cytogenetic methods, which in- 
clude Trypsin-Giemsa banding. 
Chromosome analysis failed at diagnosis. Itwas performed 
again after 1 month of conventional chemotherapy and we 
were only able to roughly analyze five cells. A karyotype with 
a t(15;17)(q22;q21) translocation was proposed. However, the 
metaphase spreads were not of adequate quality and we could 
not be sure of this diagnosis. 
A new culture was established with a sample that cor- 
responded to day 30 after RA-treatment and day 14 after che- 
motherapy. Thirty-four cells were analyzed; 14 cells showed 
a reciprocal translocation that was interpreted as t(14;17) 
(q22;q21). The remaining cells were normal. A composite 
karyotype is shown in Figure 1. 
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Figure 1 A partial karyotype from two bone marrow metaphases 
showing t(14;17) (q22 ;q21). Normal chromosomes 13and 15 also are 
shown. Arrows indicate abnormal chromosomes. 
The next analysis was performed at day 38 after RA- 
treatment and day 22 after chemotherapy. All 35 observed 
cells were normal. 
DISCUSSION 
To our knowledge, only a single case of APL with a t(14;17) 
has been reported [9]. As the authors uggest, his rearrange- 
ment may represent a variant of t(15;17) in the same way as 
variant translocations have been described for t(9;221 in 
chronic myeloid leukemia. Thus, our case represents a recur- 
rent variant translocation that involves, cytogenetically, only 
chromosomes 14 and 17. 
Prior to the molecular studies and looking to the variant 
translocations in APL, there was a scientific ontroversy about 
which was the most essential chromosomal segment involved 
in the pathogenesis of this disease. It seemed that, because 
of the higher number of reported cases with anomalies of 
17q, the changes affecting the long arm of chromosome 17 
were more important [10] than those affecting the long arm 
of chromosome 15. Our case would have supported this hy- 
pothesis, however, since the understanding of the molecu- 
lar events is associated with the t(15;17), it is obvious that 
both changes are equally essential. 
Moreover, Ogawa et al. [6] described a case of APL show- 
ing a complex translocation and demonstrated molecular 
rearrangements leading to the PML/RARa fusion gene simi- 
lar to those described for the common t(15;17) [8]. As these 
authors propose, it is likely that this molecular rearrange- 
ments occurs in other variant and complex translocations 
seen in APL. 
In the absence of molecular analysis, the clinical response 
to treatment with retinoic acid, as seen in our case, would 
represent an indirect evidence of a rearrangement of the 
RARu gene. Conventional chemotherapy was unsuccessful, 
and only when treatment with retinoic acid was started, alone 
or combined with other drugs, was complete remission 
achieved. This evidence justifies the role of the RARa gene 
rearrangement i  he disease but, unfortunately, tells noth- 
ing about whether the rearrangement also involves the PML 
gene. It has been proposed that the genetic events in APL 
with variant ranslocations could resemble those occurring 
in CML, which always involve BCR and ABL rearrangements 
[8, 10]. However, more molecular studies are needed to 
documentate such a hypothesis. 
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